**Seniors Gain $50 Access to GLP-1 Weight Loss Drugs** Medicare will soon offer eligible beneficiaries a new pathway to certain GLP-1 medications used for weight management. The Centers for Medicare & Medicaid Services is launching the Medicare GLP-1 Bridge demonstration on July 1, 2026. This short-term program runs through December 31, 2027, and sets a flat $50 monthly copay for approved drugs.[[1]](https://www.cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge) The move

– Zepbound in the KwikPen formulation
– Foundayo These selections focus on formulations approved for weight reduction. Regular Part D coverage for diabetes indications, such as Ozempic, remains unchanged and separate from this pilot.[3] **What Comes Next** The Bridge serves as a bridge to the longer BALANCE Model, which CMS plans to roll out in 2027. Participants who continue needing the medications after 2027 will transition into that framework through participating Part D plans.[4] For now, the demonstration provides a concrete, time-limited opportunity for qualifying seniors to access these treatments at a predictable cost. Providers and beneficiaries should watch for detailed guidance from CMS in the coming weeks as the July 1 start date approaches.